Clinical trials are how new treatments and improved outcomes are developed in health care. Highlands Oncology Group has been participating in clinical trials for over 20 years. Our Research Department operates numerous clinical trials in both oncology and hematology. New experimental medications, or different ways to use existing medications, are compared to the currently available treatments in order to advance cancer care for patients around the world.
Each clinical trial has certain criteria that must be met to participate. These guidelines help protect the safety of each patient. There are four phases of clinical trial development:
- Phase I – Assessing medication dose and safety
- Phase II – Further assessing safety and efficacy
- Phase III – Comparison to currently available medications
- Phase IV – Further study of already FDA-approved medications
Phase I clinical trials provide new, novel approaches for the treatment of cancer. Highlands Oncology Group has the privilege of being the only community based Phase I oncology clinical trial center in the state of Arkansas. Cancer research is always evolving and new treatments emerge every year. Highlands Oncology Group stays at the cutting edge of technology with help from the Research Department and clinical trials.
We strive to provide as many options as possible for the treatment of cancer. Only you and your doctor can decide if a clinical trial is right for you. If you are interested in participating in a clinical trial, please review our list of currently enrolling clinical trials. For further information on clinical trials, please visit http://www.clinicaltrials.gov.
For questions or more information, please contact the Research Department:
- By email: research@hogonc.com
- By phone: 479-872-8130
- Contact Highlands Oncology Group: 479-587-1700
| SGN35-015: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T cell lymphoma (PTCL) in adults age 60 and above | LYMPHOMA | 11/27/2019 | View Here |
| Nektar Prople 16-214-05: A phase 1/2, open-label, multicenter study to investigate the safety and preliminary efficacy of NEKTAR-214 plus Pembro in patients with locally advanced or metastatic solid tumors. | LUNG - Non Small Cell Cancer (NSCLC) | 11/14/2019 | View Here |
| Nektar Prople 16-214-05: A phase 1/2, open-label, multicenter study to investigate the safety and preliminary efficacy of NEKTAR-214 plus Pembro in patients with locally advanced or metastatic solid tumors. | MELANOMA | 11/14/2019 | View Here |
| Nektar Prople 16-214-05: A phase 1/2, open-label, multicenter study to investigate the safety and preliminary efficacy of NEKTAR-214 plus Pembro in patients with locally advanced or metastatic solid tumors. | OTHER | 11/14/2019 | View Here |
| Nektar Prople 16-214-05: A phase 1/2, open-label, multicenter study to investigate the safety and preliminary efficacy of NEKTAR-214 plus Pembro in patients with locally advanced or metastatic solid tumors. | HEAD/NECK | 11/14/2019 | View Here |
| S1826: A Phase III, Randomized Study of Nivolumab (Opdivo) plus AVD or Brentuximab Vedotin (Adcetris) plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma | LYMPHOMA - Hodgkins | 11/01/2019 | View Here |
| CO41101: A Phase III, double-blind, placebo controlled, randomized study of Ipatasertib in combination with Atezolizumab and Paclitaxel as a treatment for patients with locally advanced unresectable or metastatic triple-negative breast cancer | BREAST | 10/29/2019 | View Here |
| BMS CA209-76k: A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy with Nivolumab versus Placebo after Complete Resection of Stage IIB/C Melanoma | MELANOMA | 09/24/2019 | View Here |
| APG-115-US-002: A Phase Ib/II Study of APG-115 in Combination with Pembrolizumab in Patients with Unresectable or Metastatic Melanomas or Advanced Solid Tumors | OTHER | 09/10/2019 | View Here |
| M16-438: A phase 1 study evaluating the safety, pharmacokinetics, and anti-tumor activity of ABBV-321 in subjects with advanced solid tumors associated with overexpression of the epidermal growth factor receptor (EGFR). | OTHER | 07/25/2019 | View Here |
| 2018-689-00US1: A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-689 in Patients with Relapsed or Refractory Lymphoma | LYMPHOMA | 07/02/2019 | View Here |
| CMBG453B12201: A randomized, double-blind, placebo-controlled phase II multi-center study of IV MBG453 added to hypomethylating agents in adult subjects with intermediate, high or very high-risk myelodysplastic syndrome (MDS) as per IPSS-R criteria | OTHER | 05/21/2019 | View Here |
| IMMU-132-09: A Phase III study of Sacituzumab Govitecan (IMMU-132) versus Treatment of Physicians Choice (TPC) in subjects with HR+, HER- metastatic breast cancer who have failed at least two prior chemotherapy regimens | BREAST | 04/23/2019 | View Here |
| M17-327: A Phase I study of SC-011 as a Single-Agent and in Combination with ABBV-181 in Subjects with Relapsed or Refractory Small Cell Lung Cancer. | LUNG - Small Cell Cancer (SCLC) | 04/17/2019 | View Here |
| J1O-MC-JZHB: A Phase Ib study of LY3295668 Erbumine (an AurA inhibitor) Monotherapy in Patients with Platinum-Sensitive, Extensive-Stage Small-Cell lung Cancer. | LUNG - Small Cell Cancer (SCLC) | 03/25/2019 | View Here |
| MS100070.0176: An open label, multicenter follow up Study to collect long term data on participants from multiple avelumab (MSB0010718C) clinical studies | OTHER | 03/08/2019 | View Here |
| Chronos-3: A Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Copanlisib in combination with Rituximab in patients with relapsed indolent B-Cell non-Hodgkins Lymphoma: Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytoid Lymphoma/Waldenstrom Macroglobulinemia, Marginal Zone Lymphoma | LYMPHOMA - Non Hodgkins (NHL) | 10/08/2018 | View Here |
| B9991033: A Phase 1b/2 Study To Evaluate Safety And Clinical Activity Of Avelumab In Combination With Binimetinib With Or Without Talazoparib In Patients With Locally Advanced Or Metastatic Ras-Mutant Solid Tumors | OTHER | 08/21/2018 | View Here |
| D8730C00001: “A Phase I, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Ascending Doses of AZD4635 Both as Monotherapy and in Combination in Patients with Advanced Solid Malignancies” | OTHER | 08/16/2018 | View Here |
| C3441020: Phase 2, non-randomized, open label, single arm, multi-center study of Talazoparib for neoadjuvant treatment of germline BRCA ½ Mutation patients with early triple neg breast CA | BREAST | 08/14/2018 | View Here |
| S1609 DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors | OTHER | 04/10/2018 | View Here |
| WO40181: A Phase II, open-label, randomized study to compare the efficacy of Venetoclax in combination with Fulvestrant compared with Fulvestrant alone in women with ER+ HER2-, inoperable, locally advanced or metastatic breast cancer who experienced disease recurrence or progression during or after treatment with CDK4/6 therapy for at least 8 weeks. | BREAST | 03/23/2018 | View Here |
| CA209914: “CheckMate 914” A Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse. | RENAL CELL | 05/24/2017 | View Here |
| CA209592: Phase 2, exploratory study of Nivolumab in combination with Ipilimumab in Subjects with Treatment-Naïve Stage IV or recurrent NSCLC | LUNG - Non Small Cell Cancer (NSCLC) | 05/09/2017 | View Here |
| UTX-TGR-204: A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304 | LEUKEMIA - Chronic Lymphocytic | 04/21/2017 | View Here |
| BBI-DSP7888-201G: A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination with Bevacizumab versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy | GLIOBLASTOMA | 04/17/2017 | View Here |
| S1418: A Randomized Phase III Trial To Evaluate The Efficacy and Safety of MK3475(Pembrolizumab) As Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With equal or > 1CM Residual Invasive Cancer | BREAST | 03/23/2017 | View Here |
| Tesaro TSR-042: Garnet A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors | OTHER | 02/28/2017 | View Here |
| ML28897-PRO02: A Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib, and Vismodegib in Patients who have advanced solid tumors with mutations or gene expression abnormalities predictive of response to one of these agents. | OTHER | 08/12/2014 | View Here |
| I3Y-MC-JPBH: A Phase 1b Study of Abemaciclib in Combination with Therapies for Patients with Metastatic Breast Cancer | BREAST | 07/25/2014 | View Here |
| I3Y-MC-JPBL: MONARCH 2: A Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study of Fulvestrant with or without Abemaciclib, a CDK4/6 Inhibitor, for Women with Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer | BREAST | 05/30/2014 | View Here |
